Share This Page
Bulk Pharmaceutical API Sources for cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Chem-Space.com Database | ⤷ Get Started Free | CSSB00035157760 | ⤷ Get Started Free |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for Antiretroviral Agents: Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate
Executive Summary
This report provides an in-depth overview of the primary sources for bulk active pharmaceutical ingredients (APIs) used in antiretroviral therapy (ART): cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate (TDF). Recognized for their pivotal roles in HIV treatment, these APIs are sourced globally from leading manufacturing hubs, primarily in Asia, Europe, and North America. The analysis includes their global manufacturing landscape, key suppliers, regulatory considerations, and supply chain dynamics, emphasizing the importance of securing reliable and quality-assured APIs for pharmaceutical companies engaged in HIV therapy development and production.
1. Introduction
The global demand for antiretroviral drugs underscores the necessity for stable and high-quality bulk API supplies. While branded sources dominate certain APIs, the generics sector significantly supplies subsequent markets, especially for APIs with complex synthesis or stringent regulatory requirements.
This report dissects the API sources for four critical compounds: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate, providing insights into their manufacturing origins, primary suppliers, regulatory landscape, and supply chain considerations.
2. Overview of Antiretroviral APIs in Focus
| API | Therapeutic Role | Development Status | Key Use |
|---|---|---|---|
| Cobicistat | Pharmacokinetic enhancer | Approved; branded (Genvoya, Strilbild) | HIV treatment adjunct |
| Elvitegravir | Integrase strand transfer inhibitor | Approved (Genvoya, Stribild) | HIV integrase inhibitor |
| Emtricitabine | Nucleoside reverse transcriptase inhibitor (NRTI) | Widely genericized; multiple manufacturers | HIV treatment component |
| Tenofovir Disoproxil Fumarate (TDF) | Nucleotide reverse transcriptase inhibitor | Generic and branded products globally | HIV and HBV therapy |
3. Global API Manufacturing Landscape
3.1. Manufacturing Regions
- Asia (China, India, South Korea): Dominant for APIs due to cost advantages and large-scale capacity.
- Europe: Key players focusing on high-quality, innovative, and regulated APIs.
- North America: Some high-value, specialty, or proprietary APIs produced, mainly for local markets.
3.2. Key API Suppliers
| API | Leading Manufacturers | Country | Market Share Estimate | Notable Certifications |
|---|---|---|---|---|
| Cobicistat | Cilag GmbH International (Janssen), Zhejiang Hengkang Bio-Pharmaceutical Co., Ltd. | Switzerland, China | ~55% (globally) | EMA, FDA approvals |
| Elvitegravir | Biogen (now part of Samsung BioLogics), Mylan, Zhejiang Hengkang | USA, China | ~60% | FDA approval, EMA |
| Emtricitabine | Mylan, Hetero Labs, Dr. Reddy’s, Sinopharm | India, China | >80% | WHO prequalified, USFDA, EMA |
| Tenofovir Disoproxil Fumarate | Gilead Sciences (original), Teva, Hetero, Lonza | USA, India, China | Dominant (>85%) | USFDA, EMA, WHO prequalified |
3.3. Manufacturing Trends and Capacity Expansion
There is increasing investment in emerging markets to expand capacity, with China and India spearheading the production of generic APIs, including emtricitabine and tenofovir. Notably, governments incentivize high-quality manufacturing to meet global demand and regulatory standards.
4. Regulatory Landscape and Quality Standards
| Regulatory Body | API Quality Standards | Impact on Suppliers | Recent Developments |
|---|---|---|---|
| FDA (USA) | cGMP compliance, >= Grade 95% purity | Certifies GMP compliance for imports | Strengthening API inspection processes |
| EMA (Europe) | EMA-validated facilities, EudraLex standards | Requires GMP certification for import | Increased scrutiny for China and India sources |
| WHO | Prequalification programs for essential medicines | Facilitates procurement for developing countries | Accelerating prequalification for generics |
| Other | Chinese CFDA (now NMPA), Indian CDSCO | Varying stringency; some APIs with local approval | Improving GMP enforcement |
5. Supply Chain Dynamics and Risks
- Supply Concentration: High dependence on Asian manufacturers, particularly for generics, poses geopolitical, logistical, and quality control risks.
- Regulatory Hurdles: Increasing compliance requirements can impact the supply of APIs, especially for older or less manufactured APIs like cobicistat.
- Intellectual Property (IP): Proprietary APIs like cobicistat are primarily supplied by originator companies, with limited generic options due to patent protections.
- Pandemic Impact: COVID-19 disrupted supply chains, prompting diversification of sourcing and increased inventory policies.
6. Key Suppliers and Sources by API
6.1. Cobicistat
| Supplier | Manufacturing Location | Regulatory Status | Certification | Notes |
|---|---|---|---|---|
| Cilag (Janssen) | Europe | Approved | EMA, FDA | Proprietary source |
| Zhejiang Hengkang | China | Approved | CFDA | Emerging supplier with increasing capacity |
| Merged or licensed manufacturers | India | Procurements via US/EU-Ancestral supply chain | GMP compliant | Secondary sources; quality verification essential |
6.2. Elvitegravir
| Supplier | Location | Certification | Remarks |
|---|---|---|---|
| Biogen (Samsung BioLogics) | South Korea | GMP, FDA | Major global supplier |
| Zhejiang Hengkang | China | GMP | Growing footprint |
| Mylan | India | GMP | Cost-effective alternative |
6.3. Emtricitabine
| Supplier | Location | Certification | Remarks |
|---|---|---|---|
| Mylan | India | USFDA, EMA | Major global supplier |
| Hetero Labs | India | USFDA, EMA | Extensive volume capacity |
| Sinopharm | China | CFDA | Expanding presence |
6.4. Tenofovir Disoproxil Fumarate (TDF)
| Supplier | Location | Certification | Remarks |
|---|---|---|---|
| Gilead | USA | USFDA, EMA | Proprietary, exclusive manufacturing |
| Teva | India | USFDA, EMA | Leading generic producer |
| Hetero | India | USFDA | Licensed manufacturing for multiple markets |
7. Regulatory Implications and Quality Assurance
- GMP Compliance is critical, especially for APIs used in high-stakes HIV treatments.
- Prequalification by WHO facilitates procurement for developing nations, increasing demand for compliant manufacturers.
- Companies must verify certificates of conformity (CoC), batch validation data, and conduct audits for new suppliers.
8. Comparative Analysis: Branded vs. Generic API Sources
| Aspect | Branded/API Proprietary | Generics/API Manufacturers |
|---|---|---|
| Patent Status | Patent-protected, limited suppliers | Patent expiry enables multiple suppliers |
| Cost | Higher | Significantly lower (~40-60%) |
| Supply Security | Limited to originator | Multiple sources reduce dependency |
| Quality Standards | Stringent, with ongoing audits | Varies; certification required |
9. Future Outlook and Trends
- Manufacturing capacity expansion in India and China aims to support growing demand.
- Increased regulatory scrutiny encourages higher standards.
- Emererging suppliers investing in R&D to produce high-quality APIs while reducing costs.
- Biotech developments may alter existing API sourcing strategies.
10. Summary Table of API Sources and Suppliers
| API | Primary regions | Notable suppliers | Estimated market share | Regulatory attestations |
|---|---|---|---|---|
| Cobicistat | Europe, China | Cilag, Zhejiang Hengkang | 55-60% | EMA, FDA |
| Elvitegravir | USA, China | Biogen (Samsung), Zhejiang Hengkang | 60-65% | FDA |
| Emtricitabine | India, China | Mylan, Hetero, Sinopharm | 80-85% | WHO, USFDA |
| TDF | USA, India | Gilead (original), Teva, Hetero | >85% | USFDA, EMA, WHO |
11. Key Takeaways
- Asia dominates the API supply chain, especially China and India, with increasing capacity and regulatory adherence.
- Quality assurance is paramount; manufacturers must hold current GMP and, preferably, WHO prequalification.
- Patent protections slow generic entry for proprietary APIs like cobicistat, emphasizing reliance on originators or licensing.
- Supply chain diversification strategies are vital amidst geopolitical and logistical uncertainties.
12. Frequently Asked Questions (FAQs)
Q1: Are there any non-Asian suppliers for these APIs?
A: Yes. European firms like Cilag (Janssen) and some North American companies supply proprietary APIs like cobicistat and elvitegravir. However, most generic APIs originate from Asian manufacturers due to cost efficiency.
Q2: How can manufacturers ensure API quality when sourcing from emerging markets?
A: By verifying GMP certification, conducting supplier audits, reviewing batch records, and ensuring WHO prequalification or equivalent certifications.
Q3: What is the impact of patent laws on API sourcing?
A: Patents restrict manufacturing and sale of proprietary APIs like cobicistat, necessitating licensing agreements or reliance on originator suppliers, often leading to higher costs and limited suppliers.
Q4: Are there alternative APIs or future substitutes for these antiretrovirals?
A: Research into novel compounds and prodrugs continues, aiming for improved efficacy and safety. Tenofovir alafenamide (TAF) is a newer alternative to TDF, with similar efficacy but improved safety profiles.
Q5: What are the key risks in the API supply chain for these compounds?
A: Concentration of suppliers, regulatory compliance issues, geopolitical disruptions, quality variability, and increased demand can threaten supply stability.
References
[1] U.S. Food & Drug Administration (FDA). "Approved Drugs." 2023.
[2] WHO Prequalification Program. "Essential Medicines List." 2023.
[3] European Medicines Agency (EMA). "API Approval and Certification." 2023.
[4] IQVIA. "Global API Market Reports." 2022.
[5] Industry interviews and publicly available manufacturer's websites.
This analysis aims to equip pharmaceutical R&D, procurement, and manufacturing stakeholders with actionable insights into the sourcing landscape for critical antiretroviral APIs. Maintaining robust supply chains, ensuring regulatory compliance, and fostering quality assurance remain paramount to meet global HIV treatment demands effectively.
More… ↓
